Publications

Below is a collection of independent, peer-reviewed publications providing evidence for the role of AXL biology in driving immune suppression and tumor immune evasion as well as therapy resistance and cancer spread.

Scientific publications

2023 ASH poster AML/MDS

2023 SITC STK11 poster

ESMO 2023 poster – BGB008 2L NSCLC

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer – Lung Cancer (lungcancerjournal.info)

AACR 2023, AXL as a therapeutic target in STK11 mutant NSCLC

ESMO Lung 2023 Presentation

ASCO 2022, Bhalla et al.

Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC

ECCMID 2022, Jaya Nautiyal et al.

25 April 2022

Bemcentinib modulation of inflammatory, fibrotic and tissue repair pathways corresponds with favourable clinical outcomes in hospitalised COVID-19 patients demonstrating higher severity cues: a biomarker perspective

ASH 2021, Sonja Loges et al.

13th December 2021

Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results indicating Bemcentinib elicits anti-AML immune responses.

SITC 2021, Rolf A. Brekken et al.

9th November 2021

AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

ASV 2021, Mr. Dana Bohan

20th July 2021

Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Agent for COVID-19

Non-Small Cell Lung Cancer Drug Development Summit 2021, Prof. Hani Gabra

15th July 2021

Reprogramming of the Lung Cancer Tumor Microenvironment With the AXL Inhibitor Bemcentinib

ECCMID 2021, Akil Jackson

12th July 2021

Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids with or without remdesivir) in hospitalised patients with COVID-19

EAU 2021, Tony J. Chen

10th July 2021

Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of AXL-inhibiting agents

4th Annual Next Gen Immuno-Oncology Congress, Prof. Hani Gabra

1st July 2021

The role of AXL in immuno-oncology: A translational perspective

EHA 2021, Dr. Sonja Loges et al.

11 June 2021

The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408) 

ERA-EDTA 2021, Linn Hodneland Nilsson

6 June 2021

Tilvestamab, a function-blocking monoclonal antibody inhibitor of AXL RTK signalling, limits the onset of renal fibrotic changes in human kidneys ex vivo

ASCO 2021, Lauren Byers et al.

4 June 2021

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with EGFRm NSCLC: End of trial update 

Virtual Immunology 2021, Dana Bohan et al.

10 May 2021

Phosphatidylserine Receptors Enhancement of SARS-CoV-2 Entry: AXL as a Therapeutic Target for COVID-19 

CROI 2021, Wendy Maury et al.

6 March 2021

Targeting of the Receptor Tyrosine Kinase AXL by Bemcentinib prevents SARS-CoV-2 infection

WCLC 2021, Dr. Matthew Krebs et al.

29 January 2021

A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC

ASH 2020, Prof. Sonja Loges et al.

6 December 2020

The combination of AXL inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: an update from the ongoing BGBC003 Phase II Trial

ASH 2020, Prof. Uwe Platzbecker et al.

5 December 2020

Efficacy and safety of bemcentinib in patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia failing Hypomethylating Agents

SITC 2020, Professor James Spicer, PhD, FRCP

11 November 2020

A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab, in pts with previouslytreated advanced NSCLC: Updated clinical & translational analysis

 

BerGenBio R&D Day

6 November 2020

 

ENA 2020

24 - 25 October 2020

Next Gen Immuno-Oncology Congress 25 June 2020

ASH 2019, Sonja Loges et al

9 December 2019, Orlando, USA

Durable responses observed in elderly AML patients ufit for intencive chemotherapy with First-in-Class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC: Phase II open-label study.

SITC 2019, Matthew Krebs et al

8 November 2019, Maryland, USA

Oral presentation in High Impact Clinical Trials:

A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis

ESMO 2019, Oddbjørn Straume et al

30 September 2019, Barcelona, Spain

Poster Presentation:

Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

ESMO 2019, Jose M. Trigo Perez et al

28 September 2019, Barcelona, Spain

Poster Presentation:

Preliminary efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC

CICON 2019, Kjersti T. Davidsen et al

27 September 2019, Paris, France 

Poster presentation:

AXL Inhibition Improves Immunotherapy by Targeting Local and Systemic Tumor Myeloid Cross-Talk

WCLC 2019, Felip et al

07 – 10 September 2019, Barcelona, Spain

Mini-oral Presentation:
Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC

WCLC 2019, Krebs et al

07 – 10 September 2019, Barcelona, Spain

 

Poster Presentation:
A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

EHA 24, Hellesøy et al

June 13 - 16 2019, Amsterdam, Netherlands

Poster Presentation:
Single Cell Signaling Pharmacodynamics in a Phase 1b Clinical Trial of the AXL inhibitor bemcentinib in Acute Myeloid Leukemia and Myelodysplastic Syndrome

EHA 24, Loges at al

June 13 - 16 2019, Amsterdam, Netherlands

Poster Presentation:
The Combination of bemcentinib, a novel, oral, selective AXL-Inhibitor and Low-Dose Cytarabine yields Durable Responses in AML patients Unfit for Intensive Chemotherapy

ASCO 2019, Loges et al

May 31 - Jun 4 2018: Chicago, IL

Poster Presentation:
First-in-class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: a Phase II open-label study

ASCO 2019, Felip et al

May 31 - Jun 4 2018: Chicago, IL

Poster Presentation:
A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in patients with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

CCBIO, Blø et al

May 13 - 14, 2019: Bergen, Norway

Poster Presentation:
BGB149, a novel clinical stage humanised anti-AXL function blocking antibody

AACR, Ramkumar et al

Mar 29 - Apr 3, 2019: Atlanta, Georgia

Poster presentation:
Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress

AACR, Chouaib et al

Mar 29 - Apr 3, 2019: Atlanta, Georgia

Poster presentation:
AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells

AACR, Du et al

Mar 29 - Apr 3, 2019: Atlanta, Georgia

Poster presentation:
AXL is critical for pancreatic cancer progression and metastasis

ASCO Gastrointestinal Cancers Symposium, Beg et al

Jan 17 - 19, 2019: San Francisco, CA

Poster Presentation:

A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nab-paclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.

60th American Society of Hematology Meeting (ASH)

Dec 1 - 4 2018: San Diego

Poster presentation by Loges et al:

Comprehensive Analysis of the Dose Escalation, Expansion and Correlates in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

SITC, Krebs et al

Nov 7 - 11 2018: Washington DC

Late breaking abstract poster presentation:

A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage

SITC, Holt et al

Nov 7 - 11 2018: Washington DC

Poster presentation: Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma

ESMO, Holt et al

Oct 19 - 23 2018: Munich, Germany

Poster Discussion: Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials

ESMO, Schuster et al

Oct 19 - 23 2018: Munich, Germany

Poster Presentation: Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

ESMO, Medyouf et al

Oct 19 - 23 2018: Munich, Germany

Poster Discussion: The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS

World Conference of Lung Cancer, Lorens et al.

Sep 23 - 26th 2018: Toronto, Canada

World Conference of Lung Cancer, Byers et al.

Sep 23 - 26th 2018: Toronto, Canada

World Conference of Lung Cancer, Gerber et al.

Sep 23 - 26th 2018: Toronto, Canada

23rd Congress of the European Hematology Association (EHA)

Jun 14 - 17 2018, Stockholm, Sweden

Poster presentation by Loges et al.

ASCO Annual Meeting

Jun 1 - 5 2018: Chicago, IL

BerGenBio ASCO 2018 reception

The reception, which coincided with the annual American Society of Clinical Oncology (ASCO) meeting, provided stakeholders, including clinicians, investors, analysts and media, with interim data from the ongoing clinical trials of bemcentinib alone and in combination with standard of care drugs in multiple cancer indications. Presentations were made by key opinion leaders, clinical trial principle investigators and members of the BerGenBio team.

AACR Annual Meeting

Apr 14 - 18 2018: Chicago, IL

3rd Annual Immuno-Oncology Summit Europe

Mar 22nd 2018: London, UK

ASCO-SITC Clinical IO Symposium, Yule et al.

Jan 25 – 27th 2018: San Francisco, CA

ASCO-SITC Clinical IO Symposium, Loges et al.

Jan 25 – 27th 2018: San Francisco, CA